Jun 24, 2022 / 03:00PM GMT
Operator
Welcome to the BioMarin conference call to discuss the positive CHMP opinion in Europe for ROCTAVIAN. Hosting the conference call today from BioMarin is Traci McCarty, Head of Investor Relations. Please go ahead, Traci.
Traci McCarty - BioMarin Pharmaceutical Inc. - VP of IR
Thank you, Ralf, and thank you all for joining us today to discuss the positive CHMP opinion for ROCTAVIAN. On the call from BioMarin's management team are J.J. Bienaime, Chairman and CEO; Jeff Ajer, Executive Vice President, Chief Commercial Officer; Hank Fuchs, President, Worldwide Research and Development; and Greg Guyer, Executive Vice President, Chief Technical Officer.
To remind you, this nonconfidential presentation contains forward-looking statements about ROCTAVIAN and the business prospects of BioMarin Pharmaceutical Inc. including expectations regarding a positive approval decision from the European Commission for ROCTAVIAN in the third quarter of this year, the number of results in BioMarin territories affected by severe hemophilia A who will have access to ROCTAVIAN,
Biomarin Pharmaceutical Inc to Discuss Positive CHMP Opinion for ROCTAVIAN Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot